Impact of Atrioventricular Delay Optimization on Ventricular Function in Conduction System Pacing (NCT07624552) | Clinical Trial Compass
CompletedNot Applicable
Impact of Atrioventricular Delay Optimization on Ventricular Function in Conduction System Pacing
Turkey (Türkiye)39 participantsStarted 2025-10-06
Plain-language summary
Conduction system pacing has emerged as a physiological pacing strategy that preserves ventricular electrical activation and minimizes pacing-induced dyssynchrony. However, the optimal atrioventricular delay setting in patients undergoing conduction system pacing remains uncertain.
This study aims to evaluate the effects of individualized echocardiography-guided atrioventricular delay optimization on ventricular function and hemodynamic performance in patients with conduction system pacing. Echocardiographic parameters including global longitudinal strain, left ventricular ejection fraction, left ventricular outflow tract velocity-time integral, cardiac output, and diastolic function indices will be assessed before and after atrioventricular delay optimization.
The study will investigate whether optimization of atrioventricular timing provides additional mechanical and hemodynamic benefits beyond physiological ventricular activation achieved by conduction system pacing alone.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 18 and 80 years
* Permanent conduction system pacing implantation for atrioventricular block
* At least 1 month elapsed since device implantation
* Sinus rhythm at the time of enrollment
* Left ventricular ejection fraction \>40%
* Adequate echocardiographic image quality for comprehensive assessment
* Ability and willingness to provide informed consent
Exclusion Criteria:
* Permanent or persistent atrial fibrillation
* Significant valvular heart disease
* Active malignancy
* Severe systemic illness with limited life expectancy
* Sinus node dysfunction requiring alternative pacing strategies
* Inadequate echocardiographic image quality
* Inability to comply with study procedures
* Refusal to participate in the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Global Longitudinal Strain (GLS)
Timeframe: Immediately before and immediately after atrioventricular delay optimization.
Trial details
NCT IDNCT07624552
SponsorBursa Yuksek Ihtisas Training and Research Hospital